User login
Key clinical point: A substantial proportion of patients showed receptor conversion between primary breast cancer (BC) and bone metastases, which significantly impacted prognosis.
Major finding: The discordance rates between primary BC and bone metastases were 14.0%, 32.3%, and 9.7% for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2), respectively. The loss vs maintenance of hormone receptor expression was associated with worse first-line progression-free survival (adjusted hazard ratio [aHR] 3.27; P = .039) and overall survival (aHR 6.09; P = .011).
Study details: Findings are from a retrospective analysis including 93 patients with BC, pathologically confirmed bone metastasis, and ER, PgR, and HER2 status available on both primary tumor and bone metastases.
Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.
Source: Lin M et al. Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases. Int J Cancer. 2022 (Nov 21). Doi: 10.1002/ijc.34365
Key clinical point: A substantial proportion of patients showed receptor conversion between primary breast cancer (BC) and bone metastases, which significantly impacted prognosis.
Major finding: The discordance rates between primary BC and bone metastases were 14.0%, 32.3%, and 9.7% for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2), respectively. The loss vs maintenance of hormone receptor expression was associated with worse first-line progression-free survival (adjusted hazard ratio [aHR] 3.27; P = .039) and overall survival (aHR 6.09; P = .011).
Study details: Findings are from a retrospective analysis including 93 patients with BC, pathologically confirmed bone metastasis, and ER, PgR, and HER2 status available on both primary tumor and bone metastases.
Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.
Source: Lin M et al. Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases. Int J Cancer. 2022 (Nov 21). Doi: 10.1002/ijc.34365
Key clinical point: A substantial proportion of patients showed receptor conversion between primary breast cancer (BC) and bone metastases, which significantly impacted prognosis.
Major finding: The discordance rates between primary BC and bone metastases were 14.0%, 32.3%, and 9.7% for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2), respectively. The loss vs maintenance of hormone receptor expression was associated with worse first-line progression-free survival (adjusted hazard ratio [aHR] 3.27; P = .039) and overall survival (aHR 6.09; P = .011).
Study details: Findings are from a retrospective analysis including 93 patients with BC, pathologically confirmed bone metastasis, and ER, PgR, and HER2 status available on both primary tumor and bone metastases.
Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.
Source: Lin M et al. Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases. Int J Cancer. 2022 (Nov 21). Doi: 10.1002/ijc.34365